Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: Loss of PDPK1 abrogates resistance to gemcitabine in label-retaining pancreatic cancer cells

Fig. 5

Silencing of BMX, NRTK2, and PDPK1 upregulated in LRCC increases response to gemcitabine in pancreas cancer cells. a anti-BMX, NRTK2 and PDPK1 siRNA leads to increased sensitivity to gemcitabine compared to cells with intact BMX, NRTK2 and PDPK1. Full drug response curves in MiaPaCa2, Panc-1, and Nor-P1 cells including cells transfected with scramble siRNA and indicated target siRNAs are shown. Gemcitabine concentration in logM on x-axis. b Induction of apoptosis in MiaPaCa2, Panc-1, and Nor-P1 cells treated with gemcitabine upon silencing of BMX, NRTK2, or PDPK1 (compared to scramble siRNA cells)

Back to article page